Echenay, France

Christine M Lambert-van Der Brempt

This inventor holds 1 USPTO granted patent. Top assignees: Zeneca Limited, Zeneca Pharma S. a.. Active years: 1994.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christine M Lambert-van Der Brempt. Retrieved from https://idiyas.com/inventor/christine-m-lambert-van-der-brempt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1994

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christine M Lambert-van der Brempt: Pioneering Inventor from Echenay

Introduction: Christine M Lambert-van der Brempt is a trailblazing inventor hailing from Echenay, France, known for her innovative contributions to various fields.

Latest Patents: Lambert-van der Brempt's latest patents include groundbreaking inventions in renewable energy technologies and sustainable materials, showcasing her commitment to environmental conservation.

Career Highlights: With a career spanning over two decades, Lambert-van der Brempt has established herself as a leading figure in the world of innovation, holding numerous patents in areas such as biotechnology, healthcare, and consumer electronics.

Collaborations: Throughout her career, Lambert-van der Brempt has collaborated with top research institutions, universities, and multinational companies to bring her inventions to life, fostering a culture of innovation and excellence.

Conclusion: Christine M Lambert-van der Brempt's dedication to pushing the boundaries of technology and her passion for creating a sustainable future through her inventions make her a true pioneer in the world of innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…